A review of current and future medical therapies for cerebral vasospasm following aneurysmal subarachnoid hemorrhage.

J. Mocco, Brad E. Zacharia, Ricardo J Komotar, E. Sander Connolly

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

In an effort to help clarify the current state of medical therapy for cerebral vasospasm, the authors reviewed the relevant literature on the established medical therapies used for cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH), and they discuss burgeoning areas of investigation. Despite advances in the treatment of aneurysmal SAH, cerebral vasospasm remains a common complication and has been correlated with a 1.5- to threefold increase in death during the first 2 weeks after hemorrhage. A number of medical, pharmacological, and surgical therapies are currently in use or being investigated in an attempt to reverse cerebral vasospasm, but only a few have proven to be useful. Although much has been elucidated regarding its pathophysiology, the treatment of cerebral vasospasm remains a dilemma. Although a poor understanding of SAH-induced cerebral vasospasm pathophysiology has, to date, hampered the development of therapeutic interventions, current research efforts promise the eventual production of new medical therapies.

Original languageEnglish
JournalNeurosurgical focus [electronic resource].
Volume21
Issue number3
StatePublished - Nov 9 2006
Externally publishedYes

Fingerprint

Intracranial Vasospasm
Subarachnoid Hemorrhage
Therapeutics
Pharmacology
Hemorrhage
Research

Cite this

A review of current and future medical therapies for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. / Mocco, J.; Zacharia, Brad E.; Komotar, Ricardo J; Connolly, E. Sander.

In: Neurosurgical focus [electronic resource]., Vol. 21, No. 3, 09.11.2006.

Research output: Contribution to journalArticle

@article{9d7fb17f48d04658ba2d4fff326569a0,
title = "A review of current and future medical therapies for cerebral vasospasm following aneurysmal subarachnoid hemorrhage.",
abstract = "In an effort to help clarify the current state of medical therapy for cerebral vasospasm, the authors reviewed the relevant literature on the established medical therapies used for cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH), and they discuss burgeoning areas of investigation. Despite advances in the treatment of aneurysmal SAH, cerebral vasospasm remains a common complication and has been correlated with a 1.5- to threefold increase in death during the first 2 weeks after hemorrhage. A number of medical, pharmacological, and surgical therapies are currently in use or being investigated in an attempt to reverse cerebral vasospasm, but only a few have proven to be useful. Although much has been elucidated regarding its pathophysiology, the treatment of cerebral vasospasm remains a dilemma. Although a poor understanding of SAH-induced cerebral vasospasm pathophysiology has, to date, hampered the development of therapeutic interventions, current research efforts promise the eventual production of new medical therapies.",
author = "J. Mocco and Zacharia, {Brad E.} and Komotar, {Ricardo J} and Connolly, {E. Sander}",
year = "2006",
month = "11",
day = "9",
language = "English",
volume = "21",
journal = "Neurosurgical Focus",
issn = "1092-0684",
publisher = "American Association of Neurological Surgeons",
number = "3",

}

TY - JOUR

T1 - A review of current and future medical therapies for cerebral vasospasm following aneurysmal subarachnoid hemorrhage.

AU - Mocco, J.

AU - Zacharia, Brad E.

AU - Komotar, Ricardo J

AU - Connolly, E. Sander

PY - 2006/11/9

Y1 - 2006/11/9

N2 - In an effort to help clarify the current state of medical therapy for cerebral vasospasm, the authors reviewed the relevant literature on the established medical therapies used for cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH), and they discuss burgeoning areas of investigation. Despite advances in the treatment of aneurysmal SAH, cerebral vasospasm remains a common complication and has been correlated with a 1.5- to threefold increase in death during the first 2 weeks after hemorrhage. A number of medical, pharmacological, and surgical therapies are currently in use or being investigated in an attempt to reverse cerebral vasospasm, but only a few have proven to be useful. Although much has been elucidated regarding its pathophysiology, the treatment of cerebral vasospasm remains a dilemma. Although a poor understanding of SAH-induced cerebral vasospasm pathophysiology has, to date, hampered the development of therapeutic interventions, current research efforts promise the eventual production of new medical therapies.

AB - In an effort to help clarify the current state of medical therapy for cerebral vasospasm, the authors reviewed the relevant literature on the established medical therapies used for cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH), and they discuss burgeoning areas of investigation. Despite advances in the treatment of aneurysmal SAH, cerebral vasospasm remains a common complication and has been correlated with a 1.5- to threefold increase in death during the first 2 weeks after hemorrhage. A number of medical, pharmacological, and surgical therapies are currently in use or being investigated in an attempt to reverse cerebral vasospasm, but only a few have proven to be useful. Although much has been elucidated regarding its pathophysiology, the treatment of cerebral vasospasm remains a dilemma. Although a poor understanding of SAH-induced cerebral vasospasm pathophysiology has, to date, hampered the development of therapeutic interventions, current research efforts promise the eventual production of new medical therapies.

UR - http://www.scopus.com/inward/record.url?scp=33750601400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750601400&partnerID=8YFLogxK

M3 - Article

C2 - 17029348

AN - SCOPUS:33750601400

VL - 21

JO - Neurosurgical Focus

JF - Neurosurgical Focus

SN - 1092-0684

IS - 3

ER -